Press Releases

Please click on a date below to download the associated press release in PDF format. If you do not have Acrobat Reader, you can download it for free here.

October 22, 2008
Tracon Pharmaceuticals, Inc. to Present at the BIOCOM Investor Conference

October 21, 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer

October 14, 2008
Phase 1 First-in-Human Clinical Trial Results with Tracon Antibodies TRC105 and TRC093 to be Presented at the 2008 AACR-NCI-EORTC Annual Meeting

June 18, 2008
TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial with Oral TRC102, an Inhibitor of Chemotherapy Resistance, in Combination with Alimta®

February 25, 2008
First Patient Treated with Novel “First-in-Class” Anti-Cancer Drug

January 9, 2008
TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody

November 2, 2007
TRACON Pharmaceuticals to Present at the Rodman & Renshaw 9th Annual Healthcare Conference

July 11, 2007
TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment

March 16, 2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment

November 3, 2006
Tracon Pharmaceuticals, Inc. announces presentation at Rodman & Renshaw 8th Annual Healthcare Conference

October 12, 2006
Case Licenses Methoxyamine to Tracon

August 2, 2006
Tracon Pharmaceuticals appoints Charles P.Theuer, M.D., Ph.D as President and Chief Executive Officer

March 14, 2006
TRACON Pharmaceuticals assembles industry-leading management team to support development of targeted cancer therapy pipeline

April 16, 2005
Lexington Pharmaceuticals changes name to TRACON Pharmaceuticals, Inc. Lexington Pharmaceuticals announced that it has changed its name to TRACON Pharmaceuticals, Inc., and has moved the company from New York, New York to San Diego, California.

April 1, 2005
Lexington Pharmaceuticals names Bert Liang, MD MBA as President and CEO. Dr. Liang was formerly Vice President of New Ventures, at Biogen Idec.